Abeona Therapeutics, Inc. (ABEO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.91-7.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ABEO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 100.0% |
Growth built into the price is above our model estimate.
The price assumes 162.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ABEO — earnings miss
Dated 2026-08-13
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing.
Why it matters: The network grew to seven sites, but sales depend on centers moving patients through treatment. More active sites could widen access.
Supportive ifThe November 11 update names at least one new QTC that treated a patient or began collecting biopsies.
Worry ifThe November 11 update reports no new QTC patient treatments or biopsy collections since Q2.
Why it matters: The company lost $20.2 million in Q2 despite growing sales. A smaller loss would show costs are moving closer to revenue.
Supportive ifThe November 11 report shows a Q3 net loss below $20.2 million.
Worry ifThe November 11 report shows a Q3 net loss of $20.2 million or more.
Why it matters: Five patients were treated in Q2, but only four treatments brought in revenue. More failed batches could limit sales.
Worry ifThe November 11 report says at least two Q3 treatments did not bring in revenue because of low yield or failed lot release.
Less concerning ifThe November 11 report says all Q3 treatments brought in revenue, with no low-yield or lot-release failures.
Why it matters: Q2 revenue rose 31% from Q1 to $11.4 million. Another increase would show the launch is still growing.
Supportive ifIn the November 11 report, Q3 net ZEVASKYN revenue is above $11.4 million.
Worry ifIn the November 11 report, Q3 net ZEVASKYN revenue is $11.4 million or less.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$198 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $502 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,343 loss on $10,000 · 43.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A filed IND would move ABO-701 from preclinical work toward human testing. The company has set a second-half 2027 filing goal.
Supportive ifAbeona announces an ABO-701 IND filing with the FDA in the second half of 2027.
Worry ifAbeona says the filing will miss the second half of 2027 or drops the filing plan.